Individualized compared with conventional dosing of enoxaparin (Q46956267)

26 December 2017

title

Individualized compared with conventional dosing of enoxaparin (English)

1 reference

26 December 2017

author

Stephen Duffull

2

1 reference

26 December 2017

author name string

Barras MA

1

1 reference

26 December 2017

Atherton JJ

3

1 reference

26 December 2017

Green B

4

1 reference

26 December 2017

language of work or name

English

0 references

publication date

10 October 2007

1 reference

26 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

26 December 2017

volume

83

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

882-888

1 reference

26 December 2017

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Measurement of thrombosis and its prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Quantification of lean bodyweight.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

What is the best size descriptor to use for pharmacokinetic studies in the obese?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100399

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100399

1 reference

26 December 2017

1 reference

26 December 2017